6533b7d7fe1ef96bd12686d5

RESEARCH PRODUCT

Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease

Mario CottoneLivia BianconeWalter FriesMarco DapernoAnna KohnFernando RizzelloVito AnneseClaudio PapiAlessandro ArmuzziSandro ArdizzonePaolo GionchettiSilvio DaneseRenata D'incàAmbrogio OrlandoMaurizio VecchiFabiana CastiglioneMichele Comberlato

subject

medicine.medical_specialtyIBDDiseaseGuidelineGuidelinesInflammatory bowel diseaseGastroenterologyBiological drugs03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineMedicalmedicineCorticosteroidCorticosteroidsHumansIn patient030212 general & internal medicineCorticosteroids; Crohn's disease; Guidelines; IBD; Immunosuppressors; Ulcerative colitis; Hepatology; GastroenterologySocieties MedicalCrohn's diseaseSettore MED/12 - GastroenterologiaUlcerative colitiHepatologybusiness.industryImmunosuppressorsRemission InductionGastroenterologyInflammatory Bowel Diseasesmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisdigestive system diseasesClinical PracticeCrohn's diseaseUlcerative colitisItalyImmunosuppressorCorticosteroids; Crohn's disease; Guidelines; IBD; Immunosuppressors; Ulcerative colitis; Adrenal Cortex Hormones; Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Italy; Remission Induction; Societies Medical030211 gastroenterology & hepatologybusinessSocietiesImmunosuppressive Agents

description

Abstract The two main forms of intestinal bowel disease, namely ulcerative colitis and Crohn’s disease, are not curable but can be controlled by various medical therapies. The Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) has prepared clinical practice guidelines to help physicians prescribe corticosteroids and immunosuppressive drugs for these patients. The guidelines consider therapies that induce remission in patients with active disease as well as treatment regimens that maintain remission. These guidelines complement already existing guidelines from IG-IBD on the use of biological drugs in patients with inflammatory bowel diseases.

yearjournalcountryeditionlanguage
2017-06-01
10.1016/j.dld.2017.01.161http://hdl.handle.net/2108/217346